P1.01A.03 Can-Prevent-Lung Trial-Canakinumab for the Prevention of Lung Cancer: Updated Interim Clinical and Biomarker Analysis von Zhang, J.J., Salehjahromi, M., Heeke, S., Godoy, M., Tran, H., Antonoff, M., Carter, B., Ostrin, E., Le, X., Gay, C., Vailati Negrao, M., Byers, L., Lu, C., Blumenschein, G., Rice, D., Walsh, G., Rajaram, R., Lin, S., Hofstetter, W., Mehran, R., Vaporciyan, A., Moghaddam, S., Lee, J.J., Wu, J., Heymach, J.

Volltext

IA34 The YAP/FOXM1 Axis Regulates EMT-Associated EGFR Tyrosine Kinase Inhibitor Resistance and Increased Expression of Spindle Assembly Checkpoint Components von Nilsson, M.B., Sun, H., Robichaux, J., Diao, L., Xi, Y., Tong, P., Sheng, L., Hofstad, M., Kawakami, M., Le, X., Liu, X., Fang, Y., Poteete, A., Vailati Negrao, M., Tran, H., Dmitrovsky, E., Peng, D., Gibbons, D., Wang, J., Heymach, J.V.

Volltext

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity von Robichaux, Jacqulyne P., Elamin, Yasir Y., Vijayan, R.S.K., Nilsson, Monique B., Hu, Lemei, He, Junqin, Zhang, Fahao, Pisegna, Marlese, Poteete, Alissa, Sun, Huiying, Li, Shuai, Chen, Ting, Han, Han, Negrao, Marcelo Vailati, Ahnert, Jordi Rodon, Diao, Lixia, Wang, Jing, Le, Xiuning, Meric-Bernstam, Funda, Routbort, Mark, Roeck, Brent, Yang, Zane, Raymond, Victoria M., Lanman, Richard B., Frampton, Garrett M., Miller, Vincent A., Schrock, Alexa B., Albacker, Lee A., Wong, Kwok-kin, Cross, Jason B., Heymach, John V.

Volltext

Activity of adagrasib (MRTX849) in patients with KRAS G12C -mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial von Sabari, Joshua K., Spira, Alexander I., Heist, Rebecca Suk, Janne, Pasi A., Pacheco, Jose M., Weiss, Jared, Gadgeel, Shirish M., Der-Torossian, Hirak, Velastegui, Karen, Kheoh, Thian, Christensen, James G, Negrao, Marcelo Vailati

Volltext

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation von Spira, Alexander I., Riely, Gregory J., Gadgeel, Shirish M., Heist, Rebecca Suk, Ou, Sai-Hong Ignatius, Pacheco, Jose Maria, Johnson, Melissa Lynne, Sabari, Joshua K., Leventakos, Konstantinos, Yau, Edwin, Bazhenova, Lyudmila, Negrao, Marcelo Vailati, Pennell, Nathan A., Zhang, Jun, Velastegui, Karen, Christensen, James G, yan, xiaohong, Anderes, Kenna Lynn, Chao, Richard C., Janne, Pasi A.

Volltext

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity von Robichaux, Jacqulyne P., Elamin, Yasir Y., Vijayan, R.S.K., Nilsson, Monique B., Hu, Lemei, He, Junqin, Zhang, Fahao, Pisegna, Marlese, Poteete, Alissa, Sun, Huiying, Li, Shuai, Chen, Ting, Han, Han, Negrao, Marcelo Vailati, Ahnert, Jordi Rodon, Diao, Lixia, Wang, Jing, Le, Xiuning, Meric-Bernstam, Funda, Routbort, Mark, Roeck, Brent, Yang, Zane, Raymond, Victoria M., Lanman, Richard B., Frampton, Garrett M., Miller, Vincent A., Schrock, Alexa B., Albacker, Lee A., Wong, Kwok-kin, Cross, Jason B., Heymach, John V.

Volltext

Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non–small-cell Lung Cancer (NSCLC) von Elamin, Yasir Y., Gomez, Daniel R., Antonoff, Mara B., Robichaux, Jacqulyne P., Tran, Hai, Shorter, Melissa K., Bohac, Jadi M., Negrao, Marcelo Vailati, Le, Xiuning, Rinsurogkawong, Waree, Lewis, Jeff, Lacerda, Lara, Roarty, Emily B., Swisher, Stephen G., Roth, Jack A., Zhang, Jianjun, Papadimitrakopoulou, Vassiliki, Heymach, John V.

Volltext

Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer von Mitchell, Kyle Gregory, Diao, Lixia, Tran, Hai T., Negrao, Marcelo Vailati, Karpinets, Tatiana, Wang, Jing, Parra Cuentas, Edwin Roger, Corsini, Erin M, Reuben, Alexandre, Federico, Lorenzo, Bernatchez, Chantale, Vaporciyan, Ara A., Swisher, Stephen, Cascone, Tina, Wistuba, Ignacio Ivan, Heymach, John, Zhang, Jianjun, Gibbons, Don Lynn, Haymaker, Cara L., Sepesi, Boris

Volltext

Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC von Negrao, Marcelo Vailati, Raymond, Victoria M., Lanman, Richard B., Ng, Patrick Kwok Shing, Nagy, Rebecca, Banks, Kimberly, Zhu, Viola Weijia, Amador, Bianca E, Roarty, Emily, Chae, Young Kwang, Clarke, Jeffrey Melson, Crawford, Jeffrey, Ou, Sai-Hong Ignatius, Gandara, David R., Heymach, John, Bivona, Trever Grant, McCoach, Caroline Elizabeth

Volltext

Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity von Robichaux, Jacqulyne P., Elamin, Yasir Y., Vijayan, R. S. K., Nilsson, Monique B., Hu, Lemei, He, Junqin, Zhang, Fahao, Pisegna, Marlese, Poteete, Alissa, Sun, Huiying, Li, Shuai, Chen, Ting, Han, Han, Negrao, Marcelo Vailati, Ahnert, Jordi Rodon, Diao, Lixia, Wang, Jing, Le, Xiuning, Meric-Bernstam, Funda, Routbort, Mark, Roeck, Brent, Yang, Zane, Raymond, Victoria M., Lanman, Richard B., Frampton, Garrett M., Miller, Vincent A., Schrock, Alexa B., Albacker, Lee A., Wong, Kwok-kin, Cross, Jason B., Heymach, John V.

Volltext